肾移植受者对肾细胞癌 (RCC) 的易感性显着升高，特别是在其原生肾脏中，而不是同种异体移植肾。在本次系统范围审查中，对 MEDLINE 和 EMBASE 数据库进行了详尽的搜索。收集了与同种异体移植肾中出现的 RCC 相关的临床表现、供体人口统计、诊断间隔、肿瘤尺寸、组织病理学特征和治疗结果等方面的信息。搜索产生了 42 个病例报告和 11 个回顾性队列的语料库，涵盖 274 名患者的队列。大多数病例（75.4%）具有临床潜伏性，主要通过影像学方式识别。症状表现包括血尿、血清肌酐水平升高、腹部不适和移植相关疼痛等表现。肾移植和肾细胞癌诊断之间的平均时间间隔计算为 11.6 年，尽管存在相当大的差异。值得注意的是，乳头状和透明细胞肾细胞癌成为普遍的组织病理学亚型。然而，纵向随访数据的缺乏是一个值得注意的警告。这项调查强调了由于无症状肾细胞癌病例的大量流行，严格的移植后监测制度的必要性。未来的研究应重点关注筛查实践的临床结果和成本效益，以制定预防策略。版权所有 © 2024 贝勒大学医学中心。

Renal transplant recipients confront a substantially elevated susceptibility to renal cell carcinoma (RCC), particularly in their native kidneys as opposed to allografts.In this systematic scoping review, exhaustive searches were conducted of the MEDLINE and EMBASE databases. Information was gathered on clinical manifestations, donor demographics, diagnostic intervals, tumor dimensions, histopathological characteristics, and therapeutic outcomes associated with RCC arising in allograft kidneys.The searches yielded a corpus of 42 case reports and 11 retrospective cohorts, encompassing a cohort of 274 patients. The majority of cases (75.4%) were clinically latent, discerned primarily through imaging modalities. Symptomatic presentations encompassed manifestations such as hematuria, elevated serum creatinine levels, abdominal discomfort, and graft-related pain. The mean temporal interval between renal transplantation and RCC diagnosis was calculated at 11.6 years, albeit displaying considerable variance. Notably, papillary and clear cell RCC emerged as the prevailing histopathological subtypes. However, the paucity of longitudinal follow-up data represents a notable caveat.This investigation underscores the imperative of rigorous posttransplant surveillance regimes owing to the substantial prevalence of asymptomatic RCC instances. Future research should focus on clinical outcomes and cost-effectiveness of screening practices to develop preventive strategies.Copyright © 2024 Baylor University Medical Center.